Novo Nordisk to reduce Wegovy list price by 50% in 2027

Novo Nordisk will reduce the U.S. list prices of its diabetes and weight-loss medications, Ozempic and Wegovy, by up to 50%, effective January 1, 2025. The new price for both drugs will be $675 per month, representing a 50% decrease for Wegovy and a 35% reduction for Ozempic. The price cuts will also apply to all doses of Wegovy and Rybelsus pills, reflecting the company’s commitment to improving affordability amid a competitive market and shifting healthcare landscape.

Want More Context? 🔎